心力衰竭中的脱血:医疗和器械疗法
Zachary L Cox1,2, Kevin Damman3, Jeffrey M Testani4
1Department of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, TN, USA.
Nature reviews. Cardiology
|April 28, 2025
概括
循环利尿剂是心力衰竭拥堵的标准,但残留拥堵仍然存在,导致结果不佳. 本综述探讨了新的医疗和设备策略,以改善脱塞和心力衰竭管理.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床试验 临床试验
背景情况:
- 心力衰竭是全球住院的主要原因之一.
- 拥堵是心力衰竭症状和入院的主要驱动因素.
- 循环利尿剂是阻塞的标准治疗方法,但往往会留下残留液体.
研究的目的:
- 审查新兴的医疗和设备策略,以改善心力衰竭患者的脱血.
- 解决关于新型脱疗法的临床试验设计的问题.
- 评估新疗法对结血,脏和出院后结果的益处.
主要方法:
- 关于当前和新兴的脱拥堵策略的文献综述.
- 对新型心力衰竭治疗的临床试验设计考虑因素的分析.
- 讨论针对流体过载的医疗和基于设备的干预措施.
主要成果:
- 医院出院后的残留拥堵与不良心力衰竭结果和再入院有关.
- 许多医疗和基于设备的策略正在调查中,以改善降低拥堵.
- 需要最佳的试验设计,以量化新疗法对标准护理的益处.
结论:
- 改进的解压策略对于更好的心力衰竭结果至关重要.
- 新兴疗法有可能解决当前治疗方法的局限性.
- 需要进一步的研究和精心设计的试验来验证新的方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: Diuretics
277
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
277
Heart Failure Drugs: β-Blockers
259
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259
Heart Failure Drugs: Inotropic Agents
401
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
401
Upper Respiratory Drugs: Decongestants
112
Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in...
Most decongestants are readily available over-the-counter in...
112
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K


